ImmunityBio, Inc. (IBRX) surged 7.23% on strong earnings and ratings upgrade.

From Yahoo Finance: 2025-05-20 12:43:00

Wall Street’s main indices had a mixed day, with the Nasdaq dropping by 0.18%. The Dow Jones grew by 0.65% and the S&P 500 rose by 0.41%. ImmunityBio, Inc. (IBRX) surged by 7.23% following strong earnings and ratings upgrade. Revenues soared by 41,192% to $16.5 million, driven by Anktiva’s performance in treating non-muscle invasive bladder cancer. Two investment firms recommended a “buy” on IBRX, with price targets of $8 and $6. IBRX ranks 6th on the list of surging stocks, but AI stocks may offer higher returns. Check out the report on the cheapest AI stock for more promising investment opportunities.



Read more at Yahoo Finance: Why ImmunityBio, Inc. (IBRX) Surged Last Week